Trial · NCT03822832
Adverse events108
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 108
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eye pruritus | Eye disorders | Placebo (Week 1-16) and if no Treatment, Week 16-28 | 1 | 18 | |
| other | Eye pruritus | Eye disorders | Spesolimab (Week 1-16) and no Treatment (Week 16-28) | 0 | 33 | |
| other | Eye pruritus | Eye disorders | Spesolimab (Open Label Period, Week 16-44) | 0 | 22 | |
| other | Abdominal distension | Gastrointestinal disorders | Placebo (Week 1-16) and if no Treatment, Week 16-28 | 1 | 18 | |
| other | Abdominal distension | Gastrointestinal disorders | Spesolimab (Week 1-16) and no Treatment (Week 16-28) | 0 | 33 | |
| other | Abdominal distension | Gastrointestinal disorders | Spesolimab (Open Label Period, Week 16-44) | 0 | 22 | |
| other | Nausea | Gastrointestinal disorders | Placebo (Week 1-16) and if no Treatment, Week 16-28 | 1 | 18 | |
| other | Nausea | Gastrointestinal disorders | Spesolimab (Week 1-16) and no Treatment (Week 16-28) | 1 | 33 | |
| other | Nausea | Gastrointestinal disorders | Spesolimab (Open Label Period, Week 16-44) | 0 | 22 | |
| other | Beta haemolytic streptococcal infection | Infections and infestations | Placebo (Week 1-16) and if no Treatment, Week 16-28 | 1 | 18 | |
| other | Beta haemolytic streptococcal infection | Infections and infestations | Spesolimab (Week 1-16) and no Treatment (Week 16-28) | 0 | 33 | |
| other | Beta haemolytic streptococcal infection | Infections and infestations | Spesolimab (Open Label Period, Week 16-44) | 0 | 22 | |
| other | Conjunctivitis | Infections and infestations | Placebo (Week 1-16) and if no Treatment, Week 16-28 | 1 | 18 | |
| other | Conjunctivitis | Infections and infestations | Spesolimab (Week 1-16) and no Treatment (Week 16-28) | 0 | 33 | |
| other | Conjunctivitis | Infections and infestations | Spesolimab (Open Label Period, Week 16-44) | 0 | 22 | |
| other | Folliculitis | Infections and infestations | Placebo (Week 1-16) and if no Treatment, Week 16-28 | 2 | 18 | |
| other | Folliculitis | Infections and infestations | Spesolimab (Week 1-16) and no Treatment (Week 16-28) | 3 | 33 | |
| other | Folliculitis | Infections and infestations | Spesolimab (Open Label Period, Week 16-44) | 1 | 22 | |
| other | Nasopharyngitis | Infections and infestations | Placebo (Week 1-16) and if no Treatment, Week 16-28 | 1 | 18 | |
| other | Nasopharyngitis | Infections and infestations | Spesolimab (Week 1-16) and no Treatment (Week 16-28) | 2 | 33 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03822832/events